Study Aiming at Researching Diagnostic Markers for the Recognition of Precancerous States, Tracking, Follow-up, and the Identification of New Therapeutic Targets for Mesothelioma in Patients With Atypical Mesothelial Hyperplasia.
- Determine if mesothelin and osteopontin in serum can serve as early markers of
malignant transformation into mesothelioma.
- Determine if there are cytological, histological, immunohistochemical, and molecular
markers of precancerous disease in tissue samples.
- Determine if SV40 has a carcinogenic role.
- Determine the relationship between the serum concentration of mesothelin and/or
osteopontin and the expression of other markers and with clinical progression.
OUTLINE: This is a multicenter study.
Levels of mesothelin and osteopontin in serum (and pleural fluid, if effusion is present)
are measured at baseline and 3, 6, 12, and 24 months. Patients with mesothelioma, reactional
lesions, or adenocarcinoma undergo tomodensitometry (TDM) at baseline, 3, 6, and 12 months.
Patients with pleural plaques only undergo TDM at 12 months.
Patients are followed for 5 years.
Mesothelin and osteopontin concentrations in serum
University Hospital, Caen